Skip to main content

David Huberman works closely with Israeli and domestic clients, representing issuers and underwriters on capital raising transactions, including private and public offerings. He regularly represents Israeli companies in their initial public offerings on U.S. stock exchanges and advises on ongoing compliance with U.S. securities laws. David’s clients include pharmaceutical and technology companies currently traded, or on their way to the Nasdaq.

Concentrations

  • Capital markets
  • Initial public offerings (IPOs)
  • Public and private offerings of equity and debt
  • Dual listings and American depositary facilities
  • Securities Exchange Act reporting and compliance obligations
  • Israeli practice

Capabilities

Experience

  • Judicial Clerk, Illinois Commerce Commission, 2010-2011

Recognition & Leadership

  • Listed, IFLR1000: Middle East and Egypt: Capital Markets, "Notable Practitioner," 2024
  • Chambers Global, Corporate/M&A: International Firms (Expertise Based Abroad), Team Member, 2022-2024
  • Listed, The Best Lawyers in America, "Ones to Watch," Securities/Capital Markets, 2023-2024
  • BDICode (Israel)
    • Recognized, International Commercial, Prominent Leaders, 2016-2024
    • Recognized, Capital Markets, Prominent Leaders, 2024
    • Recognized, Hi-Tech, Prominent Leaders, 2021-2024  
  • Dun's 100 (Israel)
    • Recognized, International Commercial, Prominent Team, 2022-2024
    • Recognized, Hi-Tech, Notable Law Firm, 2022-2024
  • Ranked, LegallyIsrael100, Capital Markets, 2022
  • Listed, The Legal 500, Israel, 2020

Credentials

Education
  • J.D., magna cum laude, Chicago-Kent College of Law, Illinois Institute of Technology, 2011
    • Certificate in International and Comparative Law
  • B.A., magna cum laude, Bradley University, 2007
Admissions
  • Illinois
  • Israel
^ Attorneys in the Tel Aviv office do not practice Israeli law.
Languages
  • English, Native
  • Hebrew, Fluent
  • Spanish, Conversational

Related Capabilities

Corporate Capital Markets Mergers & Acquisitions Venture Capital & Emerging Technology Life Sciences & Medical Technology Food, Beverage & Agribusiness